Marvin Feldman
Hematology & Oncology · Baltimore, MDNPI 1336254424
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,945 of the $47,353 with a category attached, or 71.7%. Lilly USA, LLC accounts for 83.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $31,422 and has fallen 78.6% since, to $6,718 in 2021. Among hematology & oncology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $307.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$39K
- Boehringer Ingelheim$4K
- GSK$2K
- E.r. Squibb & Sons, L.L.C.$446
- Novartis$369
- Exelixis Inc.$271
- plus $1K from 19 others
Across 7 payments — averaging $81,046 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$541K
- TG Therapeutics, Inc.$27K
What the payments were for
- Consulting fees$5,17511%
- Speaking & faculty fees$33,94572%
- Travel & lodging$4,3329%
- Food & beverage$3,8038%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 92 | $39,344 |
| Boehringer Ingelheim | 4 | $3,823 |
| GSK | 2 | $1,939 |
| E.r. Squibb & Sons, L.L.C. | 9 | $446 |
| Novartis | 5 | $369 |
| Exelixis Inc. | 4 | $271 |
| Sanofi | 5 | $254 |
| Daiichi Sankyo Inc. | 2 | $210 |
| Incyte Corporation | 3 | $140 |
| Eisai Inc. | 1 | $106 |
| Genentech USA, Inc. | 5 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| AstraZeneca(2 entities) | 3 | $46 |
| Johnson & Johnson | 3 | $42 |
| Pfizer | 3 | $40 |
| Gilead | 2 | $33 |
| Seagen Inc. | 2 | $31 |
| Amgen | 1 | $25 |
| EMD Serono, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Array Biopharma Inc | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,353 in reported general payments places this provider in the 90th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Baltimore
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Huzefa BahrainBaltimore$102K
- Tania JainBaltimore$95K
- Josephine FelicianoBaltimore$72K
- Abhijeet KumarBaltimore$66K
- Michael AuerbachBaltimore$64K
- Suman RaoBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.